Paper Review Records
All Paper Review Records
15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Comparative Effectiveness of Sacubitril/Valsartan Versus Sodium-Glucose Cotransporter 2 Inhibitors among Patients with Heart Failure with Reduced Ejection Fraction with or without Diabetes: A Cohort Study
Munaza Riaz; Steven M. Smith; David E. Winchester; Eric A. Dietrich; Haesuk ParkShow moreShow less
1. Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, USA; 2. Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, USA; 3. Division of Cardiovascular Medicine, Department of Medicine, College of Medicine, University of Florida, Gainesville, USA; 4. Department of Pharmacy Education and Practice, College of Pharmacy, University of Florida, Gainesville, USAShow moreShow less
When Methods Matter: An Umbrella Review of Lorundrostat and the Impact of Analytical Decisions on Reported Blood Pressure and Safety Outcomes
Zeyad Elariny; Omar Salem; Mohamad Ashraf Salaheldin; Adham Ahmed; Farida Rabie; Maryam Mohamed Sayed; Mohamed Harish; Mohamed Ali; Selim Ahmed Eliwa; Mohammad Elshorbagy; Sara ElHarouni; Ahmed Abdelmeguid; Retaj Ahmed; Omnia Azmy NabehShow moreShow less
1. Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo, Egypt; 2. Faculty of Medicine, Benha National University, Obour City, Egypt; 3. Lecturer of Pharmacology, Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo, EgyptShow moreShow less
Aspirin Versus Clopidogrel as Single Antiplatelet Therapy After TAVI: A Propensity Score-Matched, Retrospective Analysis
Anastasios Apostolos; Konstantinos Konstantinou; Mohammed Allaf; Athanasios Sakalidis; Konstantinos Kalogeras; Ee Ling Heng; Simon Davies; Alison Duncan; Miles Dalby; Saeed Mirsadraee; Tarun Mittal; Aigul Baltabaeva; Tito Kabir; Mohammed Majid Akhtar; Robert Smith; Vasileios PanoulasShow moreShow less
1. Royal Brompton and Harefield Hospitals, Guy’s and St. Thomas’ NHS Foundation Trust, London, UK; 2. Faculty of Medicine, Imperial College London, London, UK; 3. National Heart and Lung Institute, Imperial College London, London, UKShow moreShow less
Empagliflozin in STEMI Patients: A Randomized Controlled Trial on Left Ventricular Recovery and Cardiovascular Outcomes
Fatemeh Baharvand; Roxana Mehran; Francesca Maria Di Muro; Alieh Mohammadi; Mohammadreza Aghajankhah; Shiva Parvaneh; Niloufar Akbari Parsa; Soheil Hassanipour; Ehsan Aboutaleb; Yaser Jenab; Somayeh Bashiri AliabadiShow moreShow less
1. Department of Cardiology, Healthy Heart Research Center, Heshmat Hospital, School of medicine, Guilan University of Medical Sciences, Rasht, Iran; 2. The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, USA; 3. Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran; 4. Department of Pharmaceutics, School of pharmacy, Guilan University of Medical Sciences, Rasht, Iran; 5. Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, IranShow moreShow less
Food Effects on the Pharmacokinetics of Single Dose and Steady-State Ralinepag, a Novel Oral Prostacyclin Agonist, in Healthy Volunteers
Daniel Lachant; Cristian E. Botta; George Giannakoulas; Natalie Patzlaff; Scott Seaman; Meredith Broderick; Maria Guido; Søren Mellemkjær; Zeenat SafdarShow moreShow less
1. University of Rochester Medical Center, Rochester, USA; 2. Department of Heart Failure and Pulmonary Arterial Hypertension, Sanatorio Privado San Gerónimo, Santa Fe, Argentina; 3. Aristotle University of Thessaloniki, Thessaloniki, Greece; 4. United Therapeutics Corp, Durham, USA; 5. UC Health, Cincinnati, USA; 6. Aarhus University Hospital, Aarhus, Denmark; 7. Houston Methodist Lung Center, Houston, USA; 8. HMRI, Houston, USA; 9. Weill Cornell College of Medicine, New York, USA; 10. Texas A&M College of Medicine, Bryan, USAShow moreShow less
Using Artificial Intelligence to Identify Patterns and Predictors of Adverse Drug Reactions in Cardiovascular Patients: A Comprehensive Narrative Review
Erfan Shahabinejad; Fatemeh Soflaei-Shahrbabak; Marzieh Gholami Shoa; Aida Azhdarimoghaddam; Mehrdad Mozafar; Pouya Yektaee-Rad; Samar Monajemi; Shayan Ghanouni; Shuhao Qiu; Mani Khorsand AskariShow moreShow less
1. Student Research Committee, Rafsanjan University of Medical Sciences, Rafsanjan, Iran; 2. USERN Office, Rafsanjan University of Medical Sciences, Rafsanjan, Iran; 3. Faculty of Pharmacy, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran; 4. Student Research Committee, Zahedan University of Medical Sciences, Zahedan, Iran; 5. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; 6. Faculty of Medicine, Guilan University of Medical Sciences, Rasht, Iran; 7. Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran; 8. Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran; 9. Department of Medicine, University of Toledo, Toledo, USAShow moreShow less
FAQ
How long does American Journal of Cardiovascular Drugs take to review a manuscript?
As of 2026-11-18, CrushSCI has 15 complete review records for American Journal of Cardiovascular Drugs. The fastest paper went from submission to acceptance in 30 days (Author’s Reply to: “Comment on: Colchicine for the Secondary Prevention of Cardiovascular Diseases: A Cumulative-Dose Meta-analysis of Randomized Controlled Trials Including 31,397 Subjects Worldwide”, received 2026-03-31, accepted 2026-04-30); the slowest took 373 days. The average is 177.2 days and the median is 186 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
